Hematopoietic stem cell transplants from unrelated donors

Immunological Reviews

Volumn 157, Issue , 1997, Pages 141-151

  Hansen, John A ^a   Petersdorf, Effie ^b   Martin, Paul J ^b   Anasetti, Claudio ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HLA DQ ANTIGEN; HLA DR ANTIGEN; METHOTREXATE;

ACCURACY; ACUTE LEUKEMIA; DNA POLYMORPHISM; GENETIC DISORDER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN DONOR; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SAFETY; SIBLING; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LIVING DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030814420     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00979.x     Document Type: Review

References (68)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-1369.
2. Thomas ED, et al. Aplastic anemia treated by marrow transplantation. Lancet 1972;1:284-289.
3. Thomas ED, et al. Bone marrow transplantation. N Engl J Med 1975;292:832-843.
4. Thomas ED, Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983;1:517-531.
5. Hansen JA, et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In: Rose NR, Macario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. 4th ed. Washington D.C. American Society for Microbiology; 1992. p. 850-866.
6. Anasetti C, Hansen JA. Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Cambridge, MA: Blackwell Scientific Publications; 1993. p. 665-679.
7. Schipper RF, D'Amaro J, Oudshoorn M. The probability of finding a suitable related donor for bone marrow transplantation in extended families. Blood 1996;87:800-804.
8. Hansen JA, Clift RA, Thomas Ed, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-567.
9. Beatty PG, et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988;45:714-718.
10. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. The National Marrow Donor Program: how it works, accomplishments to date. Oncology 1989;3:63-74.
11. Oudshoorn M, Leeuwen A, Zanden HGMv, Rood JJv. Bone marrow donors worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994;14:3-8.
12. Hansen JA. Development of registries of HLA-typed volunteer marrow donors. Tissue Antigens 1996;47:460-463.
13. NMDP program information and statistics are available through NMDP Online. URL: http: //www.marrow.org/netscape/
14. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995;60:778-783.
15. Fleischhauer K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 1990;323:1818-1822.
16. Dennert G, Anderson CG, Warner J. T killer cells play a role in allogeneic bone marrow graft rejection but not in hybrid resistance. J Immunol 1985;135:3729-3734.
17. Colonna M, et al. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci USA 1992;89:7983-7985.
18. Anasetti C, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
19. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977;296:61-66.
20. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994;15:221-230.
21. Petersdorf EW, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997;89:1818-1823.
22. Petersdorf EW, Smith AG, Mickelson EM, Martin PJ, Hansen JA. Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain. Immunogenetics 1991;33:267-275.
23. Petersdorf EW, Stanley JF, Martin PJ, Hansen JA. Molecular diversity of the HLA-C locus in unrelated marrow transplantation. Tissue Antigens 1994;44:93-99.
24. Petersdorf EW, Hansen JA. A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. Tissue Antigens 1995;46:73-85.
25. Grunnet N, Kristiansen T, Kissmeyer-Nielsen F. Cell mediated lympholysis in man. The impact of HLA-C antigens. Tissue Antigens 1976;7:301-309.
26. Dill O, Kievits F, Koch S, Ivanyi P, Hammerling GJ. Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. Proc Natl Acad Sci USA 1988;85:5664-5668.
27. Mackall CL, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228.
28. Storb R, et al. Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992;80:560-561.
29. Sullivan KM, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259.
30. Weiden P, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979;300:1068-1073.
31. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease. N Engl J Med 1981;304:1529-1533.
32. Horowitz MM, et al. Graft-versus leukemia reactions following bone marrow transplantation in humans. Blood 1990;75:555-562.
33. Glucksberg H, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974;18:295-304.
34. Przepiorka D, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
35. Sullivan KM, et al. Chronic graft-versus-host disease: pathogenesis, diagnosis, treatment and prognostic factors. In: Baum SJ, Santos GW, Takaku F, eds. Recent advances and future directions in bone marrow transplantation. New York: Springer Verlag; 1988. p. 150-157.
36. Storb R, et al. Marrow transplantation for aplastic anemia. Semin Hematol 1984;21:27-35.
37. Martin PJ, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985;66:664-672.
38. Martin PJ, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445-456.
39. Martin PJ, Kernan NA. T cell depletion for the prevention of graft-versus-host disease in man. In: Burakoff S, Deeg MJ, Ferrara J, Atkinson K, eds. Graft versus host disease: research and clinical management. New York: Marcel Dekker; 1990. p. 371-387.
40. Beatty PG, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-771.
41. Storb R, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-735.
42. Anasetti C, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
43. Servida P, et al. Improved survival of haploidentical related donor marrow transplants mismatched for HLA-A or B versus HLA-DR. Blood 1996;88(1):484 (Abstract).
44. Mickelson EM, Guthrie LA, Etzioni R, Anasetti C, Martin PJ, Hansen JA. Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: matching for transplants from related haploidentical donors. Tissue Antigens 1994;44:83-92.
45. Mickelson EM, et al. Evaluation of the mixed lymphocyte culture (MLC) assay as a method for selecting unrelated donors for marrow transplantation. Tissue Antigens 1996;47:27-36.
46. Kaminski E, et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989;48:608-613.
47. Spencer A, et al. Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Value in donor selection. Transplantation 1995;59:1302-1308.
48. Spencer A, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995;86:3590-3597.
49. Schwarer AP, et al. Comparison of helper and cytotoxic anti-recipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994;58:1198-1203.
50. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992;327:1613-1617.
51. Schwarer AP, et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993;341:203-205.
52. Roosnek E, et al. The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings. Transplantation 1993;56:691-696.
53. Fussell ST, Donnellan M, Cooley MA, Farrell C. Cytotoxic T lymphocyte precursor frequency does not correlate with either the incidence or severity of graft-versus-host disease after matched unrelated donor bone marrow transplantation. Transplantation 1994;57:673-676.
54. Speiser DE, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996;87:4455-4462.
55. Pei Ji, et al. Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-versus-host disease and survival after unrelated marrow transplantation. (In press)
56. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992;10:333-358.
57. Sprent J, Hurd M, Schaefer M, Heath W. Split tolerance in spleen chimeras. J Immunol 1995;154:1198-1206.
58. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996;183:657-661.
59. Petersdorf EW, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995;86:1606-1613.
60. Petersdorf EW, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996;93: 15358-15363.
61. Martin PM. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared to related donors. Bone Marrow Transplant 1991;8:217-223.
62. Appelbaum FR, et al. Allogeneic marrow transplantation for chronic myeloid leukemia. Med Oncol 1994;11:69-74.
63. Sierra J, et al. Unrelated donor marrow transplants for acute leukemia. Blood 1995;86:290 (Abstract).
64. Hansen JA, Gooley T, Clift R, Petersdorf EW, Martin PJ, Anasetti C. Unrelated donor marrow transplants for patients with chronic myeloid leukemia. Blood 1995;86:123 (Abstract).
65. Slavin MA, et al. Efficacy and safely of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.
66. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-178.
67. Lanio E, Anasetti C, Longton G, Etzioni R, Bowden R, Hansen JA. Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors. Blood 1993;82:1359 (Abstract).
68. Clift RA, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994;84:2036-2043.